BioNano Genomics, Inc. (NASDAQ: BNGO) reported Q4 revenue of $2.8 million versus the consensus estimate of $4.42 million.

“2019 was a tremendous year for the acceptance, recognition, and support our Saphyr system received from world-class institutions, and we expect to see that trend continue,” said Erik Holmlin, Ph.D., CEO of Bionano. “We are seeing an increase in the number of instruments placed, indicating that Saphyr is being accepted and recognized by leaders in the field. With record highs in single quarter consumable revenues, we believe we are on the cusp of a shift towards broader adoption of our Saphyr system by world-class institutions and we are excited at the trends we see heading into 2020.”

For earnings history and earnings-related data on BioNano Genomics, Inc. (BNGO) click here.